Compound research

Semaglutide: Research Overview & Current Status

By the Best Peptide Stores Editorial TeamLast reviewed 2026-08-08 · Also known as: Ozempic, Wegovy, Rybelsus

FDA-approved

Semaglutide is a GLP-1 receptor agonist. Current research status: fda-approved. Semaglutide is FDA-approved under three brand names for distinct indications: Ozempic (type 2 diabetes, cardiovascular/kidney risk reduction), Rybelsus (oral, type 2 diabetes), and Wegovy (chronic weight management, cardiovascular risk reduction in adults with obesity/overweight and established cardiovascular disease, and MASH under accelerated approval). Compounded (non-brand) semaglutide is not FDA-approved and is subject to active FDA enforcement.

Overview

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, originally for type 2 diabetes management and later approved for chronic weight management. It is administered by subcutaneous injection (Ozempic, Wegovy) or as a daily oral tablet (Rybelsus, and more recently an oral Wegovy formulation).

GLP-1 receptor agonist

Research timeline

2017
FDA approved Ozempic (semaglutide injection) for type 2 diabetes based on the SUSTAIN trial program.
Source →
2019
FDA approved Rybelsus, the first oral GLP-1 receptor agonist, for type 2 diabetes.
Source →
2021
FDA approved Wegovy for chronic weight management based on the STEP Phase 3 trial program (STEP 1-4, >4,500 participants); STEP-1 reported 14.9% mean weight loss at 68 weeks vs 2.4% placebo.
Source →
2022
Wegovy approval extended to adolescents aged 12 and older.
Source →
2024
Wegovy approved for cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease, based on the SELECT trial (17,604 participants).
Source →
2025
Ozempic approved to reduce risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease; FDA also approved an oral Wegovy tablet based on the Phase III OASIS 4 trial (NCT05564117).
Source →

Active & recent research

Phase 3

OASIS 4 (oral semaglutide for weight loss)

efficacy and safety of a 25 mg oral semaglutide tablet for weight management

NCT05564117 on ClinicalTrials.gov →Source →

Phase 3

SELECT cardiovascular outcomes trial

cardiovascular death, nonfatal MI, and nonfatal stroke in adults with obesity/overweight and established cardiovascular disease

Source →

accelerated approval pathway, confirmatory trial ongoing

Wegovy MASH indication trials

improvement of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis

Source →

Key findings

STEP-1 (Phase 3, N=1,961) reported 14.9% mean body weight loss at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo.
SUSTAIN 6, a cardiovascular outcomes trial, reported a significant reduction in major adverse cardiovascular events versus placebo (HR 0.74) over a median follow-up of 2.1 years.
The SELECT trial (17,604 participants) established cardiovascular risk reduction in adults with overweight/obesity and established cardiovascular disease, supporting a 2024 label expansion.
OASIS 4 reported 16.6% mean weight loss at 64 weeks with full adherence to oral semaglutide 25 mg, versus 2.7% for placebo.

Safety & regulatory notes

Brand-name semaglutide (Ozempic, Wegovy, Rybelsus) is FDA-approved with an established label including boxed warnings and known GI-related adverse effects. The FDA has separately issued repeated public warnings about compounded (non-brand) semaglutide: as of mid-2025 the agency proposed permanently excluding semaglutide from the list of bulk substances 503A/503B compounders may use, and by July 2025 had received over 1,150 adverse event reports tied to compounded semaglutide and tirzepatide, many linked to dosing errors, product quality issues, and in some cases fraudulent labeling.

How this site makes money

We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →

Where it's sold for research

We haven't built a dedicated vendor-availability page for Semaglutide yet. See our full research-peptide vendor rankings →

Semaglutide FAQ

Is semaglutide FDA-approved?+

Yes, under three brand names: Ozempic and Rybelsus for type 2 diabetes (with additional cardiovascular/kidney indications for Ozempic), and Wegovy for chronic weight management and cardiovascular risk reduction.

What is semaglutide studied for?+

Approved and ongoing research covers type 2 diabetes glycemic control, chronic weight management, cardiovascular risk reduction, chronic kidney disease progression, and MASH (fatty liver disease).

Is compounded semaglutide legal and safe?+

The FDA has stated compounded semaglutide is an unapproved product that has not undergone its review for safety, effectiveness, and quality, and has documented adverse events including dosing errors and fraudulent labeling; the agency moved in 2025 to restrict compounding of semaglutide by 503A/503B facilities.

Is semaglutide the same as research-grade semaglutide sold online?+

No. FDA-approved semaglutide is manufactured, tested, and dispensed under strict pharmaceutical regulation; 'research chemical' semaglutide sold outside that system has not been reviewed by the FDA for identity, purity, or safety.

Sources for this page (6)